MWMoli Wu

Moli Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Moli Wu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting STAT3 enhances glioblastoma therapeutic sensitivity through valproic acid-mediated regulation of the tumor microenvironment

    by Leina Li, Moli Wu, Xu Zheng, Jia Liu

    Introduction: Glioblastoma (GBM) is a highly malignant tumor of the nervous system, posing serious threats to patient survival and quality of life. However, current treatment options remain limited in both availability and effectiveness. Objective: This study analyzes the gene expression data related to GBM to support the development of improved therapeutic strategies. Methods: Two gene expression datasets were selected for statistical analysis. Differentially expressed genes (DEGs) related to GBM were screened based on predefined criteria. Enrichment analysis was performed to explore the biological processes and pathways involved. A protein-protein interaction (PPI) network was constructed to identify central genes, which were further analyzed for expression patterns and their potential roles in GBM pathology. Results: A total of 1,151 overlapping DEGs were identified. Enrichment analysis revealed their involvement in several key biological processes and pathways. From the PPI network, central genes, including signal transducer and activator of transcription 3 (STAT3), CAML1, clathrin assembly lymphoid myeloid 2, and protein kinase CAMP-activated catalytic subunit beta were identified as playing crucial roles in GBM development. Immune cell subtype analysis indicated interactions between these genes and the tumor microenvironment. The diagnostic value highlighted STAT3 as a potential biomarker for GBM. In vivo experiments confirmed that gene expression patterns were consistent with database predictions. Molecular docking analysis identified valproic acid as a promising therapeutic candidate, targeting five central genes. In vitro studies demonstrated that valproic acid effectively induced GBM cell death and modulated the expression of these genes, with high safety observed. Conclusion: Identifying DEGs and central genes is essential in understanding GBM pathology. This study establishes STAT3 as a diagnostic marker and highlights valproic acid as a potential multi-target therapeutic agent. These findings lay the groundwork for more effective and targeted treatment strategies for GBM.

  • Open Access

    Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation

    by Moli Wu, Danyang Song, Hui Li, Nisar Ahmad, Hong Xu, Xiaobo Yang, Qian Wang, Xiaoxin Cheng, Sa Deng, Xiaohong Shu

    Chemoresistance blunts the efficacy of temozolomide (TMZ) in the treatment of glioblastoma (GBM). Elevated levels of O6-methylguanine-DNA methyltransferase (MGMT) and activation of signal transducer and of transcription 3 (STAT3) have been reported to correlate with GBM resistance to alkylator chemotherapy. Resveratrol (Res) inhibits tumor growth and improves drug chemosensitivity by targeting STAT3 signaling. Whether the combined therapy of TMZ and Res could enhance chemosensitivity against GBM cells and the underlying molecular mechanism remains to be determined. In this study, Res was found to effectively improve chemosensitivities of different GBM cells to TMZ, which was evaluated by CCK-8, flow cytometry, and cell migration assay. The combined use of Res and TMZ downregulated STAT3 activity and STAT3-regulated gene products, thus inhibited cell proliferation and migration, as well as induced apoptosis, accompanied by increased levels of its negative regulators: PIAS3, SHP1, SHP2, and SOCS3. More importantly, a combination therapy of Res and TMZ reversed TMZ resistance of LN428 cells, which could be related to decreased MGMT and STAT3 levels. Furthermore, the JAK2-specific inhibitor AG490 was used to demonstrate that a reduced MGMT level was mediated by STAT3 inactivation. Taken together, Res inhibited STAT3 signaling through modulation of PIAS3, SHP1, SHP2, and SOCS3, thereby attenuating tumor growth and increasing sensitivity to TMZ. Therefore, Res is an ideal candidate to be used in TMZ combined chemotherapy for GBM.


  • Open Access

    Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations

    by Meng-Di Lu, Hong Li, Jun-Hua Nie, Sheng Li, Hai-Shan Ye, Ting-Ting Li, Mo-Li Wu, Jia Liu

    Anaplastic thyroid cancer is an extremely lethal malignancy without reliable treatment. BRAFV600E point mutation is common in ATCs, which leads to MAPK signaling activation and is regarded as a therapeutic target. Resveratrol inhibits ATC cell growth, while its impact on BRAF-MAPK signaling remains unknown. This study aims to address this issue by elucidating the statuses of BRAF-MAPK and STAT3 signaling activities in resveratrol-treated THJ-11T, THJ-16T, and THJ-21T ATC cells and Nthyori 3-1 thyroid epithelial cells. RT-PCR and Sanger sequencing revealed MKRN1-BRAF fusion mutation in THJ-16T, BRAF V600E point mutation in THJ-21T, and wild-type BRAF genes in THJ-11T and Nthyori 3-1 cells. Western blotting and immunocytochemical staining showed elevated pBRAF, pMEK, and pERK levels in THJ-16T and THJ-21T, but not in THJ-11T or Nthyori 3-1 cells. Calcein/PI, EdU, and TUNEL assays showed that compared with docetaxel and doxorubicin and MAPK-targeting dabrafenib and trametinib, resveratrol exerted more powerful inhibitory effects on mutant BRAF-harboring THJ-16T and THJ-21T cells, accompanied by reduced levels of MAPK pathway-associated proteins and pSTAT3. Trametinib- and dabrafenib-enhanced STAT3 activation was efficiently suppressed by resveratrol. In conclusion, resveratrol acts as dual BRAF-MAPK and STAT3 signaling inhibitor and a promising agent against ATCs with BRAF mutation.